The agreent, which was initially announced in June, will see DOSE’s ongoing development of bioerodible and sustained-release drug delivery platforms rolled into Glaukos’ portfolio. DOSE reportedly has multiple projects currently underway, primarily focussed on the areas of age-related macular degeneration (AMD) and diabetic macular eda.{{quote-A:R-W:400-I:2-Q:“We plan to build upon the promising work DOSE Medical has already done, while leveraging our unique expertise in disruptive, micro-scale innovation” -who:Thomas Burns, Glaukos}}At the time the deal was announced, Mr Thomas Burns, president and CEO of Glaukos, said it would build on his company’s legacy as an ophthalmic pioneer.“With this acquisition, Glaukos will establish a new R&D retinal program that complents our growing glaucoma franchise and pipeline. We plan to build upon the promising work DOSE Medical has already done, while leveraging our unique expertise in disruptive, micro-scale innovation to advance exciting new treatment options for AMD and other retinal diseases,” Burns said.The transaction means that DOSE is will now once again be a wholly owned subsidiary of the company. In 2010 Glaukos spun DOSE out as a stand-alone entity, and in 2015 re-acquired the iDose line of products back from it for US$26 million (AU$37 m).In 2017, Glaukos acquired DOSE’s intraocular pressure sensor syst for US$5.5 million (AU$7.9 m), with an additional US$9.5 million (AU$13.6 m) contingent on whether several development milestones were reached. More reading:Santen and Glaukos enter MIGS distribution agreent
New evidence backs HOYA’s DIMS technology to combat myopia
HOYA Vision Care has announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple...
